Quinoline derivatives for use in the treatment of inflammation diseases

A method for treating an inflammatory disease, disorder or condition comprising administering to a patient suffering from the inflammatory disease, disorder or condition a compound of formula (IV):

• or a pharmaceutically acceptable salt thereof, wherein:
• Z is C or N;
• V is C or N;
• means an aromatic ring, wherein V is C or N, and when V is N, V is ortho, meta or para relative to Z;
• each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(═O)—R1, —NR1—C(═O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(═O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl, the alkyl being optionally mono- or di-substituted by a hydroxyl group or a group of formula (IIa):
• or a group of formula (IIIa):
• each of R1 and R2 is independently hydrogen or (C1-C3)alkyl;
• each of R3 and R4 is independently hydrogen, Li+, Na+, K+, N+(Ra)4 or benzyl;
• n is 1, 2 or 3;
• n′ is 1, 2 or 3;
• each R′ is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(═O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, a group of formula (IIa):
• or a group of formula (IIIa):
• A is a covalent bond, oxygen, or NH;
• B is a covalent bond or NH;
• m is 1, 2, 3, 4 or 5;
• p is 1, 2 or 3;
• each of Ra and Rb is independently hydrogen, (C1-C5)alkyl, or (C3-C6)cycloalkyl, or Ra and Rb form together with the nitrogen atom to which Ra and Rb are attached a saturated 5- or 6-membered heterocycle, the heterocycle optionally containing a further heteroatom chosen among N, O, S, the heterocycle being optionally substituted by one or more Ra, provided that when R′ is a group of formula (IIa) or formula (IIIa), n′ may be 2 or 3 only if other R′ groups are different from the group of formula (IIa) or formula (IIIa);
• and
• R″ is hydrogen, (C1-C4)alkyl, or a group of formula (IIa) as defined herein,
• wherein the inflammatory disease, disorder or condition being treated by the administration of the compound of formula (IV) is selected from the group consisting of:
• an inflammatory disease, disorder or condition selected from intestinal failure, Ulcerative colitis and Crohn's disease;
• and
• an inflammatory disease, disorder or condition selected from acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Juvenile rheumatoid arthritis, Systemic jubenile idiopathic arthritis (SJIA), Cryopyrin Associated Periodic Syndrome (CAPS), Muckle-Wells syndrome, and osteoarthritis.